NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics Forum

NeuroMetrix to Present at Canaccord Genuity Medical Technology & Diagnostics ForumWALTHAM, Mass.--(BUSINESS WIRE)--Nov. 7, 2013-- NeuroMetrix, Inc. (Nasdaq: NURO), www.neurometrix.com, a medical device company focused on the treatment and management of the neurological complications of diabetes, today announced that Shai N. Gozani M.D., Ph.D., President and Chief Executive Officer, is scheduled to speak at the Canaccord Genuity Medical Technology & Diagnostics Forum at The Westin Grand Central, New York, NY on November 14, 2013. Dr. Gozani intends to provide an update on the Company’s business activities with particular emphasis on its SENSUS^™ pain management system for relief of chronic intractable pain, including pain associated with diabetic neuropathy.

NeuroMetrix's presentation is scheduled for Thursday, November 14, 2013 at 8:00 am (Eastern Daylight Time). A live audio webcast will be available on the investor relations section of the corporate website - www.neurometrix.com. This webcast will be archived after the live event.

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck^® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com.

Source: NeuroMetrix

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com